Shaping the future of AMR decision-making: Munich stakeholder meeting

On 19 of April PrIMAVeRa invited key actors in antimicrobial resistance research, policy, industry and clinical development to witness and shape a live demonstration of its pioneering vaccine prioritisation platform to support development of models and visualisations to estimate the impact of vaccines and monoclonal antibodies on AMR.

In Munich, the PrIMAVeRa consortium convened a stakeholder meeting, organised by the Institute of Health Carlos III, European Clinical Research Alliance for Infectious Diseases (Ecraid) and European Vaccine Initiative (EVI), which brought together policymakers, vaccine developers, public health professionals, and researchers to collectively shape and refine a decision-support platform designed to prioritise vaccines and monoclonal antibodies as tools in the fight against antimicrobial resistance (AMR).

Two  sessions featured 1) modelling approaches to estimate vaccine and monoclonal antibodies' impact on AMR and 2) a live demonstration of a prototype dashboard demonstrating results of the modelling studies, accompanied by structured discussions on usability, data interpretation, and platform design, as well as a dedicated feedback segment to help refine the system ahead of its final release.

The interactive three-hour session, offered participants a valuable opportunity to engage directly with the platform at a critical stage of its development. Participants first explored the live prototype before contributing detailed feedback that will directly inform final design decisions.

"This meeting reinforced that robust, transparent modelling—paired with intuitive visualisations—is essential to guide vaccine and monoclonal antibody R&D, inform policy, and support real-world decisions in tackling antimicrobial resistance." - Dr Mateusz Hasso-Agopsowicz, Technical Officer at World Health Organization and consultant for PrIMAVeRa project.

During both sessions stakeholders identified that models to estimate the impact of E. Coli vaccines in preventing urinary tract infections should be prioritised. They have also emphasised that the dashboard should allow users to vary certain parameters, such as vaccine efficacy, coverage, or total infection incidence.

“The involvement of stakeholders through our stakeholder meetings has been essential in shaping the platform, ensuring it responds to real-world needs and supports meaningful, data-driven decisions to address antimicrobial resistance for policymakers, funders and industry.” – Dr Irina Meln, Head of Innovation at EVI and PrIMAVeRa project coordinator.

PrIMAVeRa, Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance, is a European public–private initiative with a clear mandate to build an open-access platform that integrates clinical, epidemiological, and health economic data to support evidence-based decision-making on combating AMR through immunisation and monoclonal antibodies.

In oder of appearance: Group photo of PrIMAVeRa members and external experts participating; Irina Meln, project coordinator (European Vaccine Initiative); Dr Mateusz Hasso-Agopsowicz, Technical Officer at World Health Organization and consultant for PrIMAVeRa project.

This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.  www.imi.europa.eu

This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.